Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 900538 in Seasonal Allergic Rhinitis
NCT00673062Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of narlaprevir in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Merck & Co. Primary endpoint: Average change from baseline in nasal congestion scores at 4 hours. Started May 2008; status: completed.
02
Drugs
narlaprevir
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00673062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00673062.